Selective concern: the 2005 report of the International Narcotics Control Board and the Need for Accountability by -
1. Background
The International Narcotics Control Board
(INCB) is a thirteen-member body of independ-
ent experts charged with monitoring implemen-
tation of three international drug control treaties
known as the UN drug conventions.  These con-
ventions oblige governments to curb the illicit
supply, traffic and consumption of narcotic and
psychotropic drugs while making such drugs
available for medical purposes.  Each year, pur-
suant to its mandate in the 1961 Single
Convention, the Board collects information
from signatory states and issues recommenda-
tions for future action to national governments
and international agencies.  
Article 14 of the 1961 Single Convention on
Narcotic Drugs permits the Board to recom-
mend actions against governments that fail to
carry out the Convention’s provisions.  These
may include opening consultations with the
offending government, proposing that the gov-
ernment carry out a national study on the issue
of drug control, or publishing a report about the
government’s non-compliance.  Beyond its for-
mal remedial powers, the INCB engages in cor-
respondence with national or local governments
on issues of concern, undertakes fact-finding
missions to some twenty countries each year,
and issues an annual report that highlights
shortcomings of non-compliant governments
and commends those deemed to have acted
appropriately.  Although formally independent
of the United Nations, INCB reports are regular-
ly invoked as a source of guidance at annual
meetings of the UN’s Commission on Narcotic
Drugs (CND) and by national governments for-
mulating law and policy.
2. The 2005 INCB report
On March 13, 2006, INCB president Hamid
Ghodse presented the Board’s 2005 report to the
49th session of the CND.  The report details
government drug control measures, while mak-
ing scant or no reference to critical issues such
as substance abuse treatment, needle and
syringe exchange to prevent HIV transmission,
or drug users’ human rights.
2.1 Treatment for substance abuse
The 2005 INCB report consistently emphasizes
drug control and concerns about drug diversion
at the expense of discussing access to drug treat-
ment.  
The Board notes that worldwide consump-
tion of methadone has increased by almost three
and one half times in the last decade (para. 103).
Rather than noting the public health benefits of
increased availability of a medication proven to
reduce demand for illicit drugs and HIV risk,
the Board raises concern about potential diver-
sion of methadone into illicit markets, and
urges governments to consider restricting
access through supervised methadone con-
sumption, short dispensing intervals, and cen-
tral registration of all opioids prescribed for
medical use (para. 75).
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The Board also considers buprenorphine—
another effective opiate substitution treat-
ment—exclusively in terms of its potential for
diversion.  In 2005, the World Health
Organization (WHO) added buprenrophine
(and methadone) to its list of essential medi-
cines.  Rather than recognizing this develop-
ment and commending the governments that
began implementing buprenorphine treatment
in 2005, the Board repeatedly references the use
of buprenorphine for illicit purposes. The 2005
report urges WHO to consider buprenorphine
diversion in determining the control status of
the medication, but makes no reference to the
substantial impact rescheduling would have on
access to substance abuse treatment or HIV pre-
vention (para. 652).
2.2 HIV prevention
The 2005 INCB report expresses concern about
HIV epidemics driven by injection drug use, yet
fails to make a single mention of strategies
proven to reduce HIV transmission among
injecting drug users such as needle and syringe
programs.
The Board notes the existence of or potential
for drug-related HIV epidemics in Afghanistan,
Azerbaijan, China, Egypt, India, Indonesia,
Kazakhstan, Lao People’s Democratic Republic,
Lesotho, Libya, Nepal, Nigeria, Malaysia,
Myanmar, Russia, Swaziland, Thailand,
Vietnam, and Zambia, as well as in Central Asia
(paras. 206, 274, 265, 300, 437, 467, 475, 478,
517, 559, 562, 572).  In many of these countries,
the Board mentions needle sharing as a source
of HIV risk.  In no case does the Board cite evi-
dence of the effectiveness of needle and syringe
programs or recommend that governments
establish such programs.  In the case of Libya,
the Board commends the government’s efforts
to combat drug-related HIV without specifying
what these efforts are (para. 265).
The Board reports on its 2005 fact-finding
mission to Russia and expresses the hope that
sufficient funds will be available to carry out
drug treatment in that country (para. 587).  Yet
the Board fails to note that the government of
the Russian Federation imposes a total ban on
substitution treatment despite an HIV epidemic
that is highly concentrated among injecting
drug users.  Instead, the Board commends the
commitment of the Russian government to
addressing the problem of drug abuse and drug
trafficking (para. 572).
The Board expresses regret at the opening of
a drug injection room in Norway, stating that
such facilities violate international drug control
treaties and urging the government of Norway
to comply (para. 590).  In so doing, the Board
fails to note a September 2002 analysis by the
legal affairs section of the United Nations Drug
Control Programme (UNDCP) which concluded
that efforts to reduce injection drug users’ expo-
sure to HIV pathogens—the central purpose of
drug injection rooms—could be considered
treatment of the kind mandated by the 1961 and
1971 drug conventions. 
In 2004, Bulgaria passed legislation punish-
ing possession of any amount of illicit drugs
with imprisonment of between three to five
years.  Since the passage of this legislation, the
number of new injection drug users in Bulgaria
has not declined, while rates of needle sharing,
drug overdose, and heroin dependence in
prison have all increased.  Reporting on its June
2005 fact-finding mission to Bulgaria, the INCB
notes only that the government has the “political
commitment and the will to deal with drug
abuse, drug trafficking and organized crime”
(para. 614).  
3. Conclusion
Drug abuse and its harms cannot be solved by
law enforcement alone.  As a body of experts
responsible for monitoring and guiding the
global response to illicit drugs, the INCB has an
obligation to address issues of drug abuse treat-
ment and HIV prevention, and to do so using
clear standards of evidence and appropriate cri-
teria for evaluating success or failure.  The 2005
report, by contrast, expresses only selective con-
cern and treats public health as an issue of
minor importance. 
